Altria GroupMO
▲ PositiveRegulationrelevance
Altria sues FDA over review delays, seeking faster approvals for its on! nicotine pouches, which could boost its smoke-free growth.
Impact on stocks 1
Consumer Staples
Altria GroupAltria Group, the maker of Marlboro cigarettes, is suing the U.S. Food and Drug Administration over its review system for new tobacco products, claiming the agency has failed to meet the required 180-day timeline and has left legal products at a disadvantage. The company, which is expanding its smoke-free portfolio, says its on! nicotine pouches have been caught in a regulatory backlog, with shipment volume topping 177 million cans in 2025 and an 8.2% retail share of the oral tobacco category. The FDA counters that its backlog dropped by about 70% in 2025 and that its nicotine-pouch pilot produced its first authorizations in December 2025. A faster, more predictable approval process could help Altria grow its smoke-free business, but a legal victory does not guarantee product approvals, and the company still faces competition and the long-term decline in cigarette volumes.
Altria GroupAltria sues FDA over review delays, seeking faster approvals for its on! nicotine pouches, which could boost its smoke-free growth.